HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-01EMA Authorised: Tenofovir disoproxil Viatris (previously Tenofovir disoproxil Mylan) (tenofovir disoproxil) — Viatris Limited
Authorised status for Tenofovir disoproxil Viatris (tenofovir disoproxil) by Viatris Limited for HIV infections in the EU.
-
EMA approval · 2026-06-12EMA Authorised: Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (efavirenz;emtricitabine;tenofovir disoproxil maleate) — Mylan Pharmaceuticals Limited
European Medicines Agency authorises a fixed-dose combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil for HIV i…
-
EMA approval · 2026-04-16EMA Authorised: Emtricitabine / Tenofovir alafenamide Viatris (emtricitabine;tenofovir alafenamide fumarate) — Viatris Limited
EMA authorised a fixed-dose combination antiretroviral therapy (emtricitabine/tenofovir alafenamide) by Viatris Limited for HIV infections.
-
EMA approval · 2026-04-07EMA Authorised: Viramune (nevirapine) — Boehringer Ingelheim International GmbH
The European Medicines Agency authorised Viramune (nevirapine) by Boehringer Ingelheim International GmbH for the treatment of HIV infection…
-
EMA approval · 2026-03-26EMA Authorised: Ritonavir Viatris (previously Ritonavir Mylan) (ritonavir) — Viatris Limited
The EMA authorised Ritonavir Viatris (ritonavir) for HIV infection, with Viatris Limited as the marketing authorization holder.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-03-12FDA Approved: SUNLENCA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for Sunlenca (lenacapavir sodium) from Gilead Sciences, Inc., reflecting an approved update to i…
-
FDA approval · 2026-03-04FDA Approved: EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE — Original Application (Laurus Labs Limited)
FDA approves a generic fixed-dose combination of emtricitabine, rilpivirine, and tenofovir disoproxil fumarate from Laurus Labs Limited (AND…
-
FDA approval · 2026-02-27FDA Approved: PREZCOBIX — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for PREZCOBIX (darunavir ethanolate and cobicistat) from Janssen Products, LP.
-
EMA approval · 2026-02-26EMA Authorised: Yeytuo (lenacapavir sodium) — Gilead Sciences Ireland Unlimited Company
EMA authorised Yeytuo (lenacapavir sodium) from Gilead Sciences Ireland Unlimited Company for HIV infections including HIV-1 infection. This…
-
EMA approval · 2026-02-26EMA Authorised: Sunlenca (lenacapavir sodium) — Gilead Sciences Ireland Unlimited Company
EMA authorised Sunlenca (lenacapavir) for HIV infections, granting EU marketing authorisation to Gilead Sciences Ireland Unlimited Company.
-
EMA approval · 2026-02-16EMA Authorised: Dovato (dolutegravir sodium;lamivudine) — ViiV Healthcare B.V.
The European Medicines Agency has authorised Dovato, a fixed-dose combination tablet of dolutegravir and lamivudine, from ViiV Healthcare fo…
-
EMA approval · 2026-02-13EMA Authorised: Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris (emtricitabine;rilpivirine hydrochloride;tenofovir alafenamide fumarate) — Viatris Limited
The European Medicines Agency authorised a fixed-dose combination HIV therapy containing emtricitabine, rilpivirine and tenofovir alafenamid…
-
FDA approval · 2026-01-29FDA Approved: RILPIVIRINE — Original Application (Somerset Therapeutics, LLC)
FDA approved the original application for rilpivirine (RILPIVIRINE) as a generic product from Somerset Therapeutics, LLC.
-
EMA approval · 2026-01-28EMA Authorised: Genvoya (elvitegravir;cobicistat;emtricitabine;tenofovir alafenamide) — Gilead Sciences Ireland UC
The EMA authorised Genvoya, a fixed-dose combination antiretroviral therapy for HIV infection, manufactured by Gilead Sciences Ireland UC. T…
-
EMA approval · 2026-01-26EMA Authorised: Triumeq (dolutegravir sodium;lamivudine;abacavir (as sulfate)) — ViiV Healthcare B.V.
The EMA has authorised Triumeq, a fixed-dose combination of dolutegravir, lamivudine, and abacavir, for treating HIV infection. The product …
-
EMA approval · 2026-01-19EMA Authorised: Kivexa (abacavir;lamivudine) — ViiV Healthcare BV
The European Medicines Agency authorised Kivexa, a fixed-dose combination of abacavir and lamivudine, for HIV infections. ViiV Healthcare BV…
-
EMA approval · 2026-01-19EMA Authorised: Ziagen (abacavir) — ViiV Healthcare B.V.
The European Medicines Agency authorised Ziagen (abacavir) for HIV infections, with ViiV Healthcare B.V. as the marketing authorization hold…
-
EMA approval · 2026-01-19EMA Authorised: Trizivir (abacavir (as sulfate);lamivudine;zidovudine) — ViiV Healthcare BV
EMA has authorised Trizivir, a fixed-dose combination of abacavir (as sulfate), lamivudine, and zidovudine, for HIV infections, under ViiV H…
-
EMA approval · 2026-01-12EMA Authorised: Celsentri (maraviroc) — ViiV Healthcare B.V.
The European Medicines Agency authorised Celsentri (maraviroc) for HIV infections, with ViiV Healthcare B.V. as the marketing authorization …
-
EMA approval · 2025-12-11EMA Authorised: Darunavir Viatris (previously Darunavir Mylan) (darunavir) — Viatris Limited
EMA authorised the darunavir product Darunavir Viatris for HIV infections. This is the generic version of darunavir (formerly marketed as Da…
-
EMA approval · 2025-12-09EMA Authorised: Eviplera (emtricitabine;rilpivirine hydrochloride;tenofovir disoproxil fumarate) — Gilead Sciences International Ltd
The EMA authorised Eviplera, a fixed-dose combination of emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate, for HI…
-
EMA approval · 2025-12-03EMA Authorised: Delstrigo (doravirine;lamivudine;tenofovir disoproxil fumarate) — Merck Sharp & Dohme B.V.
EMA authorised Delstrigo, a fixed-dose combination tablet of doravirine, lamivudine and tenofovir disoproxil fumarate, for HIV infections. T…
-
EMA approval · 2025-12-02EMA Authorised: Kaletra (lopinavir;ritonavir) — AbbVie Deutschland GmbH & Co. KG
The European Medicines Agency authorised Kaletra (lopinavir/ritonavir) for HIV infections, with AbbVie Deutschland GmbH & Co. KG as the mark…
-
FDA approval · 2025-11-26FDA Approved: CABENUVA — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for CABENUVA (cabotegravir and rilpivirine) from ViiV Healthcare Company. This action updates th…
-
EMA approval · 2025-11-19EMA Authorised: Descovy (emtricitabine;tenofovir alafenamide) — Gilead Sciences Ireland UC
EMA authorised Descovy (emtricitabine and tenofovir alafenamide) for HIV infections; MAH: Gilead Sciences Ireland UC.